Bill, "I am not short TXB stock, but if speculation drives it to a point wher it becomes marginable, I will be." This stock is marginalbe; why wouldnt it be? It trades over $5, and it is not foriegn, and the SEC has put no restrictions on it. Concerning the above past financing, as I have said before, it is the only thing I have heard negative about this stock. There more recent financing was a much better deal for the shareholders. The institutions that rate this a strong buy are well aware of the financing that you mentioned. There have been several in depth research reports done on TXB, and it is consistently rated a strong buy. Concerning their products, who cares if they were developed in house or not? If TXB owns them and they are profitable, then TXB succeeds. TXB has been for awhile, and continues to be, one of the top speculative Biotechs.
I still have not heard anything to change my mind. Perhaps if you could give me some hard evidence as to why Novastan will not be approved by the FDA, then I would sell. If is is approved by the FDA first quarter 1998, like predicted, it will cause the stock to at least double, IMO.
Brad |
